SI-BONE Inc. reported record performance in its latest investor presentation, highlighting approximately 20% worldwide revenue growth for fiscal year 2025, with preliminary figures reaching $200.8 to $200.9 million. U.S. revenue also saw a notable increase of about 21%, totaling between $190.9 and $191.0 million. The company achieved net cashflow breakeven for the third consecutive quarter and added around 250 U.S. physicians in the fourth quarter, bringing its active U.S. physician base to approximately 1,640, an 18% increase year-over-year. SI-BONE operates in a market estimated at over $3 billion, with less than 10% penetration to date and more than 140,000 procedures performed using its products. The portfolio includes three breakthrough-designated devices and is supported by over 200 peer-reviewed publications and four randomized controlled trials. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SI-BONE Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.